Information about Invega Hafyera: Its forms, strengths, administering methods, and related details
Invega Hafyera is a brand-name injectable solution used for managing schizophrenia in adults. Produced by Johnson & Johnson, this extended-release liquid suspension comes in two strengths and is administered by a healthcare professional.
The active ingredient in Invega Hafyera is paliperidone palmitate. It is given as an intramuscular injection, most likely into the buttocks muscle, and is usually provided in a clinical setting such as a doctor's office or pharmacy.
Invega Hafyera is designed to be given once every six months, although the exact dosage may vary based on several factors. The dosage is determined by the doctor, taking into account the severity of schizophrenia, the strength of the most recent dose of Invega Sustenna or Invega Trinza, and how well the kidneys function.
If you miss an appointment to receive your Invega Hafyera injection, it's crucial to call your healthcare professional to reschedule and discuss the next steps. It's also important to note that the starting dose of Invega Hafyera may depend on the most recent dose of Invega Sustenna or Invega Trinza if you are switching from those medications.
For more information on Invega and its dosage, you can refer to its prescribing information. It's essential to understand the details of your treatment to ensure its safety and effectiveness.
While Invega Hafyera has been thoroughly studied, there have been rare reports of overdoses with the oral tablet form of paliperidone (Invega). In the case of receiving too much Invega Hafyera, call your doctor right away or contact America's Poison Centers (800-222-1222) or use its online resource. If you have severe symptoms, immediately call 911 (or your local emergency number) or go to the nearest emergency room.
It's worth mentioning that there were no reports of overdoses in studies of Invega Hafyera. This injectable solution belongs to a group of drugs called atypical antipsychotics and has been designed as a long-term treatment. Its use may be continued long-term if it's safe and effective for the condition.
In some cases, if it's been more than six months and three weeks since your last dose of Invega Hafyera, your doctor may decide to restart once-per-month Invega Sustenna injections.
Always remember to discuss any concerns or questions you may have about your treatment with your healthcare professional. They are there to help ensure your treatment is as safe and effective as possible.
